Zhu Weiming

Weiming Biopharma, a core subsidiary of the Sinobioway Group, is a leading Chinese biotechnology company focused on the development and commercialization of biologics and innovative therapies. The company is best known for its production of recombinant human interferon alpha-2b (Anferon) and its significant investments in vaccine development and cell therapy. It operates as a major industrialization base for Peking University's life science research, bridging the gap between academic discovery and large-scale manufacturing. Weiming Biopharma has a diverse portfolio spanning infectious diseases, oncology, and autoimmune disorders, and it maintains a strong presence in the Chinese domestic market through its listed entity on the Shenzhen Stock Exchange.